HIV Type 1 Vaccine-Induced Cytotoxic T Cell Responses: Potential Role in Vaccine Efficacy

1997 ◽  
Vol 13 (3) ◽  
pp. 205-210 ◽  
Author(s):  
GORDON L. ADA ◽  
M. JULIANA McELRATH
1991 ◽  
Vol 119 (2) ◽  
pp. 230-236 ◽  
Author(s):  
Katherine Luzuriaga ◽  
Richard A. Koup ◽  
Cheryl A. Pikora ◽  
Doreen B. Brettler ◽  
John L. Sullivan

Vaccines ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 134
Author(s):  
Zekun Mu ◽  
Barton F. Haynes ◽  
Derek W. Cain

The SARS-CoV-2 pandemic introduced the world to a new type of vaccine based on mRNA encapsulated in lipid nanoparticles (LNPs). Instead of delivering antigenic proteins directly, an mRNA-based vaccine relies on the host’s cells to manufacture protein immunogens which, in turn, are targets for antibody and cytotoxic T cell responses. mRNA-based vaccines have been the subject of research for over three decades as a platform to protect against or treat a variety of cancers, amyloidosis and infectious diseases. In this review, we discuss mRNA-based approaches for the generation of prophylactic and therapeutic vaccines to HIV. We examine the special immunological hurdles for a vaccine to elicit broadly neutralizing antibodies and effective T cell responses to HIV. Lastly, we outline an mRNA-based HIV vaccination strategy based on the immunobiology of broadly neutralizing antibody development.


2005 ◽  
Vol 18 (4) ◽  
pp. 234-242 ◽  
Author(s):  
Silvia Garbelli ◽  
Stefania Mantovani ◽  
Belinda Palermo ◽  
Claudia Giachino

2004 ◽  
Vol 169 (12) ◽  
pp. 1322-1330 ◽  
Author(s):  
Frédéric Ebstein ◽  
Carole Sapede ◽  
Pierre-Joseph Royer ◽  
Marie Marcq ◽  
Catherine Ligeza-Poisson ◽  
...  

2010 ◽  
Vol 95 (Supplement 1) ◽  
pp. Fa33-Fa33
Author(s):  
D. Lissauer ◽  
K. Piper ◽  
P. Moss ◽  
M. Kilby

Sign in / Sign up

Export Citation Format

Share Document